Skip to main content
OpenTrials
Completed

NCT Number: NCT01852552

Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement

Multicenter, prospective, observational study in aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI) or high-risk patients undergoing aortic valve replacement (AVR).

The objectives of the study are:

1. Description of neurocognitive status before and after transcatheter aortic valve implantation and aortic valve replacement procedures 2. Description of Quality of Life (QoL) after these procedures 3. Defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities 4. Assessment of costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and costs of follow-up.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute of Cardiology, Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy

About this study

In Italy, a nation-wide observational study endorsed by the Superior Institute of Health has been previously launched in order to evaluate appropriateness and effectiveness of aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI) procedures: the OBservational Study of Effectiveness of AVR-TAVI procedures for severe Aortic steNosis Treatment (OBSERVANT). The present study was designed to complement the national survey on TAVI and AVR procedures including data about costs, cognitive functions and quality of life after these procedures. This integrated framework may help defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities and, on the other hand, should enable accurate evaluation of the impact of each kind of treatment on quality of life and neuropsychological functions. These elements could also represent relevant keys to decision-making to the different therapeutic strategies. In addition, we aim to ascertain costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and follow-up costs. Costs estimate, combined to the integrated physical and mental health status outcome for each treatment modality, may represent the background for subsequent cost-effectiveness analyses.

All consecutive patients undergoing transcatheter aortic valve implantation or aortic valve replacement (if age ≥ 80 years or Logistic Euroscore ≥ 15%) for aortic stenosis at participating centers during the period of enrollment will be included in the registry, after release of written informed consent. Allocation of patients to different treatment groups will be performed jointly by a cardiologist and a cardiac surgeon on the basis of a complete clinical framework, independently from the present study and in accordance with available guidelines. Type of treatment (for example, access site for TAVI, type of prosthesis…) will be decided by the physicians based on local clinical practice and general principles of good clinical practice.

The administration of neurocognitive and quality of life questionnaires will be performed before the procedure and after 3 months and 1 year by trained personnel following standard operation procedures defined by a coordinating unit. A telephone and web-based support for operators will be available throughout the entire duration of the study. A common methodology for data collection and analysis is defined to guarantee data reliability and homogeneity of assessments among the participating units. The cost analysis will be coordinated by the Regional Healthcare and Social Agency of the Emilia Romagna Region.

Data will be collected in a web-based database (OBSERVANT) through dedicated Case Records Forms and a final database will be built by merging this database with a separate database for costs and Hospital Discharge Records and Mortality Registry databases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All consecutive patients undergoing TAVI at participating centers during the period of enrollment
  • All consecutive patients aged ≥80 years or with Logistic Euroscore ≥15% undergoing AVR at participating centers during the period of enrollment

Exclusion criteria

  • Absence of informed consent

Treatment and study plan

Transcatheter aortic valve implantation

Device

Patients undergoing TAVI with transfemoral, transapical, or any other vascular access

Other names: Edwards Sapien XT, Corevalve, Acurate-TA

Aortic valve replacement

Procedure

Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)

Primary outcomes

  1. Mini Mental State Examination (MMSE)

    Time frame: baseline, 3-month, 12-month

    Changes in cognitive function after transcatheter aortic valve implantation and surgical aortic valve replacement

  2. Hospital Anxiety and Depression Scale (HADS)

    Time frame: baseline, 3-month, 12-month

    Changes of emotional status after transcatheter aortic valve implantation and surgical aortic valve replacement

  3. Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Time frame: baseline, 3-month, 12-month

    Changes in quality of life after transcatheter aortic valve implantation and surgical aortic valve replacement

  4. In-hospital costs

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement

    Calculation of precise hospital costs for transcatheter aortic valve implantation and surgical Aortic Valve Replacement, including costs of hospitalization, drugs and devices.

Secondary outcomes

  1. Myocardial infarction

    Time frame: 30-day, 12-month and up to 2-year (longest available follow-up)

    Incidence of myocardial infarction

  2. Stroke

    Time frame: 30-day, 12-month and up to 2-year (longest available follow-up)

    Incidence of stroke

  3. Pace-maker implantation

    Time frame: 30-day, 12-month

    Need for permanent pacing

  4. Vascular complications

    Time frame: 30-day

    Incidence of vascular complications as defined by the VARC

  5. Bleedings

    Time frame: 30-day

    Incidence of bleedings as defined by the VARC

  6. Acute kidney injury

    Time frame: 30-day

    Incidence of AKI as defined by the VARC

  7. Follow-up costs

    Time frame: 12-month

    Evaluation of costs during follow-up, including new hospital admissions, outpatient clinic and drugs

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Collaborators

  • Ministry of Health, Italy
  • Region Emilia-Romagna, Italy

Registry information

Acronym: CCQ

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
May 13, 2013
Registry last updated
Nov 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.